Trials / Active Not Recruiting
Active Not RecruitingNCT07104383
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,100 (estimated)
- Sponsor
- Viking Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly |
Timeline
- Start date
- 2025-06-23
- Primary completion
- 2027-07-01
- Completion
- 2027-08-01
- First posted
- 2025-08-05
- Last updated
- 2026-04-07
Locations
127 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07104383. Inclusion in this directory is not an endorsement.